{"product_id":"questdiagnostics-swot-analysis","title":"Quest Diagnostics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuest Diagnostics’ strong brand, extensive testing network, and recurring revenue position it well in a growing diagnostics market, but reimbursement pressures, regulatory complexity, and competition pose meaningful risks; our full SWOT unpacks these dynamics with financial context and strategic takeaways. Purchase the complete SWOT analysis to receive a professionally formatted, editable report and Excel matrix to support investing, planning, or pitching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position and Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics holds the largest US clinical lab share, processing about 240 million tests annually by end-2025, which yields unit-cost advantages smaller labs can’t match.\u003c\/p\u003e\n\u003cp\u003eThat scale supports industry-leading adjusted EBITDA margins near 15% in FY2024 and funds $500+ million annual R\u0026amp;D and capital spends for advanced diagnostics and automation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Logistics and Patient Access Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics operates over 2,200 patient service centers and a network of 4,000+ collection sites and couriers across the U.S., giving it one of healthcare’s largest logistics footprints; this reach drove 2024 specimen volumes of ~150 million tests and contributed to $11.4 billion in revenue for fiscal 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Advanced Diagnostic Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics shifted toward molecular, genomics, and oncology tests, which accounted for about 38% of service revenue by Q3 2025, up from ~24% in 2020, boosting gross margins by ~420 basis points year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese specialized tests carry average selling prices 2.6x higher than routine panels, giving Quest stronger pricing power and EBITDA margin resilience versus commoditized testing.\u003c\/p\u003e\n\u003cp\u003eFocus on precision medicine keeps Quest embedded with specialty physicians and 1,700+ hospital system contracts as of Dec 2025, securing referral volume and long-term demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Data Assets and Analytics Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuest Diagnostics holds one of the world’s largest de-identified lab databases—billions of clinical results—driving revenue streams in pharma research, population health, and surveillance; data services contributed roughly $1.1B in 2024 commercial contracts and analytics partnerships, boosting margins above core testing.\u003c\/p\u003e\n\u003cp\u003eThe company turns aggregate results into real-time disease surveillance and provider insights, enhancing stickiness with payers and health systems and supporting higher-value services beyond single-test fees.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBillions of de-identified results\u003c\/li\u003e\n\u003cli\u003e~$1.1B 2024 analytics\/commercial revenue\u003c\/li\u003e\n\u003cli\u003eUsed for pharma R\u0026amp;D, population health, surveillance\u003c\/li\u003e\n\u003cli\u003eImproves client retention and margin mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Strategic Partnerships with Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuest Diagnostics has deep clinical and lab-management ties with major hospital networks, frequently acquiring hospital outreach labs or running internal lab operations to boost efficiency and secure high-acuity testing flows.\u003c\/p\u003e\n\u003cp\u003eThese partnerships helped Quest generate about $8.2 billion in revenue in 2024, with hospital\/outreach contracts contributing materially to its approximately 30% segment margin on clinical lab services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady high-acuity test volume\u003c\/li\u003e\n\u003cli\u003eAcquisitions of outreach labs\u003c\/li\u003e\n\u003cli\u003eImproved lab operational efficiency\u003c\/li\u003e\n\u003cli\u003eStronger integration with care delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuest Diagnostics: #1 U.S. lab — $11.4B revenue, ~240M tests, 38% specialty mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics: #1 US clinical lab—~240M tests processed by end-2025, $11.4B revenue FY2024, adjusted EBITDA ~15% in FY2024, $500M+ annual R\u0026amp;D\/capex; 2,200+ patient centers, 4,000+ collection sites; molecular\/genomics\/oncology ~38% revenue by Q3 2025; data services ~$1.1B 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed (2025)\u003c\/td\u003e\n\u003ctd\u003e~240M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$11.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData services (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty test mix (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework that highlights Quest Diagnostics’s core strengths, operational weaknesses, market opportunities, and external threats shaping its competitive and strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Quest Diagnostics for fast, visual strategy alignment and executive-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Geographic Concentration in the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics earns about 95% of revenue in the United States (2024 annual report), leaving it highly exposed to U.S. economic cycles, regulatory shifts, and Medicare\/Medicaid policy changes; unlike global peers with 20–40% international sales, Quest lacks meaningful geographic hedges, so changes in U.S. insurance reimbursements or a 1–2% Medicare fee cut could materially hit margins and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Fluctuating Government Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics receives about 45% of revenue from Medicare and Medicaid; shifts like the 2014 Protecting Access to Medicare Act (PAMA) cuts and ongoing CMS price updates expose margins to policy risk.\u003c\/p\u003e\n\u003cp\u003eCMS Medicare Clinical Laboratory fee schedule reductions—example: average reimbursement declines of 10–15% in some test groups—can compress operating margin unless volume rises or pricing mix improves.\u003c\/p\u003e\n\u003cp\u003eManaging this requires ongoing network optimization, lab automation, and cost cuts; Quest reported $1.1bn of cost savings target in 2024 to offset reimbursement pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Fixed Operating and Infrastructure Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Quest Diagnostics’ ~2,000 patient service centers and national logistics fleet creates heavy fixed costs that exist even if testing volume drops; in 2024 Quest reported about $4.6 billion in operating expenses, making leverage sensitive to volume swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Integrating Frequent Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eQuest Diagnostics often grows by buying regional labs, but integrating their IT, cultures, and lab protocols creates complexity that raised operating expense inefficiencies after acquisitions in 2023–2024; Quest reported acquisition-related costs of $140 million in 2024.\u003c\/p\u003e\n\u003cp\u003eSuch integration gaps can cause temporary service slowdowns and test backlogs—patient-level turnaround time increased up to 12% in some markets post-close in 2024—risking client churn and revenue loss.\u003c\/p\u003e\n\u003cp\u003ePoor execution also drives staff turnover: acquired-lab employee attrition spiked as much as 18% in the first year after deals in 2023, threatening continuity of referral relationships.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisition-related costs: $140M (2024)\u003c\/li\u003e\n\u003cli\u003eTurnaround time up to +12% post-close (2024)\u003c\/li\u003e\n\u003cli\u003eEmployee attrition up to 18% first year (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Regulatory and Legal Compliance Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eQuest Diagnostics faces persistent regulatory risk: past settlements include a $241 million settlement in 2019 and ongoing Medicare billing scrutiny that pushed compliance costs above $200 million in 2023.\u003c\/p\u003e\n\u003cp\u003eData-privacy exposure is material—HIPAA breaches or quality lapses could trigger multi-million dollar fines, audits, and physician trust erosion, hurting referrals and revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2019 settlement: $241 million\u003c\/li\u003e\n\u003cli\u003eCompliance spend: \u0026gt;$200 million (2023)\u003c\/li\u003e\n\u003cli\u003eAudit \u0026amp; fine risk: multi‑million per incident\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuest's U.S. concentration, Medicare exposure and high costs risk margin shock\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration in the U.S. (~95% revenue, 2024) and heavy Medicare\/Medicaid mix (~45%) expose Quest to reimbursement cuts (CMS fee schedule cuts ~10–15% in some test groups), plus high fixed costs ($4.6B operating expenses, 2024) and $140M acquisition costs (2024) that drive integration issues (turnaround +12%, attrition 18%); regulatory fines ($241M settlement, 2019) and compliance spend \u0026gt;$200M (2023) raise legal\/data risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue share\u003c\/td\u003e\n\u003ctd\u003e~95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpEx\u003c\/td\u003e\n\u003ctd\u003e$4.6B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcq costs\u003c\/td\u003e\n\u003ctd\u003e$140M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnaround time post-close\u003c\/td\u003e\n\u003ctd\u003e+12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttrition post-acq\u003c\/td\u003e\n\u003ctd\u003e18% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor settlement\u003c\/td\u003e\n\u003ctd\u003e$241M (2019)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eQuest Diagnostics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752204874105,"sku":"questdiagnostics-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/questdiagnostics-swot-analysis.png?v=1772238316","url":"https:\/\/matrixbcg.com\/products\/questdiagnostics-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}